Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2025-06-26 Management Reports
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Annual MD&A - English.pdf
Management Reports Classification · 98% confidence The document is titled “Management’s Discussion & Analysis” (MD&A) for the fiscal year ended March 31, 2025. It contains a detailed discussion of financial position, results of operations, quarterly summaries, outlook, liquidity, risk factors, critical accounting estimates, etc. This corresponds exactly to the definition of a Management Report (MDA), which provides management’s detailed explanation of financial results, business trends, and outlook. It is neither just an earnings release nor an interim report, nor merely an announcement of publication. Therefore, the correct classification is MDA.
2025-06-26 English
News release - English.pdf
Earnings Release Classification · 93% confidence The document is a press release titled “Medexus Announces Strong Fiscal Year 2025 Results,” summarizing key financial and operational highlights for Q4 and fiscal year ended March 31, 2025, with revenue, net income, EBITDA figures, product launch update, and conference call details. It is not the full annual report or regulatory filing but an initial announcement of quarterly/yearly earnings results. This matches the definition of an Earnings Release. FY 2025
2025-06-26 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document begins with an Independent Auditor’s Report by PwC, detailing their opinion, audit scope, key audit matters, and auditor responsibilities, followed by the consolidated financial statements (statements of financial position, income, notes, etc.). It is a standalone audit report rather than a full annual report or earnings release. This matches the definition of Audit Report / Information (Code: AR). FY 2025
2025-06-26 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a press release scheduling an upcoming conference call to discuss Medexus’s fourth fiscal quarter and fiscal year results. It contains no financial results, MD&A text, or detailed financial disclosures itself, nor is it a transcript or financial report. It does not announce dividends, share issues, management changes, or legal proceedings. There is no investor presentation or proxy solicitation. As it does not fit any of the more specific categories, it falls into the general regulatory/fallback category (RNS).
2025-06-17 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing completion of a public reimbursement agreement for a pharmaceutical product in Quebec. It contains business‐development news and forward‐looking statements but does not present financial results, management discussion & analysis, or any formal statutory report. It is not an earnings release, annual or interim report, M&A announcement, or any other narrowly defined filing type. Therefore it falls into the fallback category of a general regulatory announcement (RNS).
2025-04-17 English
News release - English.pdf
Regulatory Filings Classification · 92% confidence The document is a corporate press release titled “Medexus Provides Update on Progress of Commercialization of GRAFAPEX,” describing operational and commercialization progress, initial uptake, product‐level margin expectations, and forward‐looking statements. It does not present quarterly or annual financial results (so it is not an Earnings Release or Annual Report), nor is it an investor presentation, proxy, or financing announcement. It is a general business update that does not fit other specific filing categories, making it a miscellaneous regulatory announcement.
2025-04-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.